Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

FDA Exploring Whether Public Shaming Can Stop REMS Abuses

Jul 19 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes

Jul 19 2017

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

Jul 04 2017

Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?

May 05 2017

Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters

Dec 04 2014

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

REMS Abuse Legislation: GPhA and PhRMA Set To Battle Again

Jun 16 2016

Related Companies

Amneal Pharmaceuticals, Inc.

Additional Topics

United States Generic Drugs Drug Safety FDA BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window